drugset
drugset / Trial / NCT05018403

First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects

NCT05018403 ↗

Phase 1 Completed 40 enrolled Aptarion Biotech AG
RandomizedSequentialQuadruple-blindTreatment

Summary

The main purpose of this study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic parameters after single ascending intravenous doses of AON-D21 in healthy male subjects.

Timeline

Start
2021-08-03
Primary completion
2022-01-05
Completion
2022-01-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AON-D21 Aptamer — Intravenous

Indications

No indication recorded.